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Abstract
Background: Preparations of mistletoe (Viscum album) are the form of cancer treatment that is most frequently used
in the complementary medicine. Previous work has shown that these preparations are able to exert cytotoxic effects on
carcinoma cells, the extent of which might be influenced by the host tree species and by the content of mistletoe lectin.
Methods: Using colorimetric assays, we have now compared the cytotoxic effects of Viscum album preparations (VAPs)
obtained from mistletoe growing on oak (Quercus robur and Q. petraea, VAP-Qu), apple tree (Malus domestica,, VAP-M),
pine (Pinus sylvestris, VAP-P) or white fir (Abies pectinata, VAP-A), on the in vitro growth of breast and bladder carcinoma
cell lines. While MFM-223, KPL-1, MCF-7 and HCC-1937 were the breast carcinoma cell lines chosen, the panel of tested
bladder carcinoma cells comprised the T-24, TCC-SUP, UM-UC-3 and J-82 cell lines.
Results: Each of the VAPs inhibited cell growth, but the extent of this inhibition differed with the preparation and with
the cell line. The concentrations of VAP-Qu, VAP-M and VAP-A which led to a 50 % reduction of cell growth (IC50) varied
between 0.6 and 0.03 mg/ml. Higher concentrations of VAP-P were required to obtain a comparable effect. Purified
mistletoe lectin I (MLI) led to an inhibition of breast carcinoma cell growth at concentrations lower than those of VAPs,
but the sensitivity towards purified MLI did not parallel that towards VAPs. Bladder carcinoma cells were in most cases
more sensitive to VAPs treatment than breast carcinoma cells. The total mistletoe lectin content was very high in VAP-
Qu (54 ng/mg extract), intermediate in VAP-M (25 ng/mg extract), and very low in VAP-P (1.3 ng/mg extract) and in VAP-
A (1 ng/mg extract). As to be expected from the low content of mistletoe lectin, VAP-P led to relatively weak cytotoxic
effects. Most remarkably, however, the lectin-poor VAP-A revealed a cytotoxic effect comparable to, or even stronger
than, that of the lectin-rich VAP-Qu, on all tested bladder and breast carcinoma cell lines.
Conclusion: The results suggest the existence of cytotoxic components other than mistletoe lectin in VAP-A and reveal
an unexpected potential of this preparation for the treatment of breast and bladder cancer.
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Breast cancer ranks as the most frequently diagnosed form
of malignant disease and the second most relevant cause
of cancer-related death in women living in Europe and
North America [1]. The progression of breast cancer can
vary considerably since this disease comprises a wide
range of malignancies that differ in invasiveness, in prog-
nosis and in the molecular characteristics of the tumor
cells. In spite of recent improvements in hormonal thera-
pies and in the use of adjuvant cytotoxic therapies, the
reduction in the overall mortality rate has been rather
modest and approximately 40 % of breast cancer patients
will eventually succumb to their disease [1].
In the United States of America, bladder cancer is the sixth
most common malignant disease and the ninth leading
cause of cancer-related deaths [2]. The majority (72 %) of
newly diagnosed bladder cancers concerns men, women
being responsible for only approximately 28 % of the
cases. The patients often (75%) suffer from superficial
bladder cancer, which is confined to the mucosa and
translates into a relatively high survival rate [2]. Patients
with unresectable or metastatic disease, however, have
low long-term survival prospects in spite of chemotherapy
treatment [2]. In general, the survival rates tend to be bet-
ter in men.
Given that the conventional therapies often lead to only
partial success, a relatively high proportion of cancer
patients have been trying treatments originating from
complementary and alternative medicine. In the case of
breast cancer, a recent clinical study involving patients
from 11 European countries revealed that some form of
complementary/alternative treatments had been used in
45 % of the cases [3]. Viscum album preparations (VAPs)
are the most commonly used form of complementary/
alternative cancer therapy. These preparations are often
used in the adjuvant setting, together with standard
chemo- or radiotherapy [3]. Post-operative treatment with
a mistletoe extract in combination with standard treat-
ment has been shown to improve quality of life and
relapse-free intervals in breast cancer patients [4,5]. Fur-
thermore, some patients could better stand aggressive
chemotherapies if receiving VAPs at the same time [5]. For
updated and critical reviews of the clinical studies con-
cerning the use of mistletoe extracts in cancer therapy see
[6,7].
In vitro experiments with cell lines and with primary cul-
tures have shown that the various VAPs can be cytotoxic to
a variety of carcinoma cells, either through the activation
of the apoptotic cascade, or by leading to necrosis [8-11].
Furthermore, these extracts have also been shown to pos-
sess immunomodulatory and anti-angiogenic properties
[12-16]. Preparations originating from mistletoe bushes
that grow in different host trees possess distinct composi-
tions and result in cytotoxic effects of varying magnitude
[10]. Furthermore, very recent work has shown that these
preparations influence the gene expression profile of
breast carcinoma cells differentially [17]. The cytotoxic
effect of VAPs is likely to be at least partially caused by
mistletoe lectin I (MLI), and the recombinant counterpart
of this protein has been shown to be a powerful agent that
is able to reduce cell proliferation and to induce apoptosis
in the 0.1–1 ng/ml concentration range [18,19]. Never-
theless, the in vitro toxicity of VAPs does not always corre-
late with their lectin content, suggesting that other
components [20] might also play a role [10,17].
In the present study, the effects of VAP-A, VAP-M, VAP-P
and VAP-Qu obtained from mistletoe growing on Abies
(white fir), Malus (apple tree), Pinus (pine), and Quercus
(oak), respectively, on the in vitro growth of several breast
and bladder carcinoma cell lines were studied.
Methods
Materials
VAP-Qu (Charge Nr. 41011), VAP-M (Charge Nr. 30611),
VAP-P (Charge Nr. 40511) and VAP-A (Charge Nr.
41111), as well as the isolated MLI were provided by His-
cia AG (Arlesheim, CH); total mistletoe lectin concentra-
tions of the preparations were determined by the
manufacturer. MLI was isolated by affinity chromatogra-
phy on lactose-Sepharose using (NH4)2SO4-precipitates
of extracts from V. album ssp. album grown on apple trees
(elution by 0.1 M lactose); MLI was not contaminated by
MLII and MLIII as controlled by SDS-gel-electrophoresis;
the concentration of MLI was determined using an ELLA-
test. 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazo-
lium bromide) (MTT) and fetal calf serum (FCS) were pur-
chased from Sigma Chemical Co. Aldrich (Switzerland),
dimethyl sulfoxide (DMSO) and trypan blue from Fluka
(Switzerland), Dulbecco's Modified Eagle's Medium high
glucose (DMEM), RPMI 1640, Dulbecco's phosphate
buffered saline (PBS) and trypsin-EDTA solution (0.25%
trypsin/0.05% EDTA) from AMIMED BioConcept (Swit-
zerland). The cell lines MFM-223 (ACC 422), KPL-1 (ACC
317), MCF-7 (ACC 115), HCC-1937 (ACC 513), T-24
(ACC 376), TCC-SUP (ACC 377) were supplied by DSMZ
(Deutsche Sammlung von Mikroorganismen und Zellkul-
turen GmbH, Germany), whereas the cell lines UM-UC-3
(CRL-1749) and J-82 (HTB-1) were purchased at ATCC
(American Type Culture Collection, Rockville, MD, USA).
Cell culture
All cell lines were cultured as recommended by the suppli-
ers and kept at 37°C in a humidified atmosphere with 5%
CO2. The cells, all of which exhibited an adherent mor-
phology, were sub-cultured twice a week by washing withPage 2 of 7
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37°C for 5 min.
Cell growth assay
Cells were seeded at the density of 105 cells/ml in 100 μl/
well (or 10,000 cells/well), in a 96-well polycarbonate
plate and incubated for 24 hours at 37°C and 5 % CO2.
Thereafter, the cells were exposed to different concentra-
tions of appropriate dilutions of VAPs, purified MLI or
blank medium (control) for 48 h, in a total volume of 200
μl/well. The previously described MTT-colorimetric assay
was then used to estimate cell growth [9]. In brief, 20 μl of
a 5 mg/ml MTT solution were added to each well. After 4
h at 37°C, 200 μl DMSO (Fluka, Switzerland) were added
to each well, the plates were gently shaken for 10 min, and
finally 25 μl Sørensen's buffer (0.1 M glycine, 0.1 M NaCl,
pH 10.5) were added and the absorbance was measured at
570 nm on a microplate reader (MRX, Dynatech Labora-
tories) against 620 nm. The absorbance value of cells
treated with culture medium and vehicle control was
taken as 100 % cell growth. The toxic effect of each dilu-
tion of the mistletoe preparations was calculated by taking
the OD mean value of sixteen treatment-wells relative to
the OD mean value of twenty-four control-wells, unless
mentioned in the context. Each experiment was repeated
at least twice. Data are shown as mean ± S.D. Note that in
this assay cell growth reflects the total mitochondrial
reducing ability of the cell populations, which itself is
strongly influenced by the corresponding proliferation
rate (in a positive way) and by the occurrence of cell death
(in a negative way).
IC50 determination
The data used for determining the concentrations of VAPs
and of MLI which resulted in a 50% inhibition of cell
growth (IC50) were collected in colorimetric MTT-assays
performed as described above. The assays included the
following concentrations of mistletoe preparations: 4, 2,
1, 0.5, 0.1, 0.01 and 0.001 mg/ml. In the case of the assays
with MLI, 1000, 100, 10 and 1 ng/ml were tested. Compu-
ter-aided curve fitting and statistical analyses were per-
formed using the commercially available software
package IGOR Pro (Version 4.0.8.0, Wavemetrics, Inc.,
10200 SW Nimbus, G-7, Portland, OR 97223, USA). The
curves were modeled using the following sigmoid fit for a
logarithmic scale: y = A2 + (A1-A2)/(1 + (x/x0)^p). The
confidence level was set at 68 %.
Results
Effect of VAPs on the in vitro growth of the KPL-1, MCF-7, 
HCC-1937 and MFM-223 breast carcinoma cell lines
Fig. 1 shows that each of the tested VAPs was able to
inhibit the in vitro growth of the MCF-7, HCC-1937, KPL-
1 and MFM-223 breast carcinoma cells. However, the
extent of this inhibition varied markedly with the prepa-
ration and with the cell line. While MCF-7 cells reacted
similarly to VAP-A, VAP-M and VAP-Qu, the remaining
cell lines exhibited some preference for one of these prep-
arations. Confirming previous observations [17], VAP-P
exhibited the weakest effect on all breast carcinoma cells.
To better compare the effects of the various VAPs on the
different breast carcinoma cells, the corresponding IC50
values after 48 hours of treatment were calculated and are
depicted in Table 1. The data show that MFM-223 cells
were most sensitive to VAP-A (IC50 of 0.05 mg/ml), HCC-
1937 cells to VAP-M (IC50 of 0.10 mg/ml) and VAP-Qu
(IC50 of 0.11 mg/ml), and KPL-1 cells to VAP-Qu (IC50
value of 0.10 mg/ml).
Effect of purified MLI on the in vitro growth of the breast 
carcinoma cell lines KPL-1, MCF-7, HCC-1937 and MFM-
223
Since MLI has often been considered to be responsible for
the cytotoxic effect of mistletoe extracts, the inhibitory
effect of isolated MLI on breast carcinoma cell growth was
studied. Purification and characterization of ML I was per-
formed as described under Methods. The IC50 values of
MLI calculated for the various breast carcinoma cell lines
are depicted in Table 1. They are 300–3000 times lower
than those obtained with VAPs. Furthermore, the sensitiv-
ity profile of the different breast carcinoma cell lines
towards MLI did not parallel the sensitivity profile
towards VAPs. MFM-223 cells were by far more sensitive
to MLI than all the other cell lines, whereas KPL-1, MCF-7
and HCC-1937 were almost equally sensitive to VAP-M.
Treatment with MLI affected breast cancer cell morphol-
ogy, being associated with a more round form, smaller
size, formation of cell-aggregates and detachment from
the surface (data not shown).
Effect of VAPs on the in vitro growth of the bladder 
carcinoma cell lines T-24, TCC-SUP, UM-UC-3 and J-82
Fig. 2 shows that VAPs were able to inhibit the in vitro
growth of each of the tested bladder carcinoma cell lines.
The IC50 values obtained with the various bladder carci-
noma cells were determined after 48 hours of treatment
and are depicted in Table 2. Each of the four bladder car-
cinoma cell lines tested turned out to be highly sensitive
to the various mistletoe preparations, especially if one
compares the results to those obtained with the above
mentioned breast carcinoma cell lines (Table 1). With the
exception of VAP-P, which again had the weakest effect on
cell growth, the IC50 values of the VAPs ranged between
0.03 and 0.60 mg/ml (Table 2). We point out that the lec-
tin-poor VAP-A and the lectin-rich VAP-Qu had compara-
tively strong effects on all bladder cell lines.
Lectin content and strength of cytotoxicity
The mistletoe lectin contents of the VAPs used in the
experiments described above are shown in Table 3 (M.Page 3 of 7
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Effects of VAPs on breast carcinoma cell growthFigure 1
Effects of VAPs on breast carcinoma cell growth. MCF-7, HCC-1937, KPL-1 and MFM-223 breast carcinoma cells were treated 
with different concentrations of VAP-Qu (❍), VAP-M (), VAP-P (Ќ) or VAP-A (), during 48 hours. Thereafter cell growth 
was determined using the MTT-colorimetric assay and the data were calculated as described under Methods. The growth of 
cells kept under comparable experimental conditions but in the absence of VAPs and of MLI (untreated control) was taken as 
100 %. Each experiment was repeated at least twice. Data are shown as mean ± S.D.
KPL-1 MFM-223
HCC-1937MCF-7
Table 1: Concentrations of various VAPs and MLI that are able to inhibit the growth of MFM-223, KPL-1, HCC-1937 and MCF-7 breast 
carcinoma cell lines by 50 % (IC50 values).
MFM-223 KPL-1 MCF-7 HCC-1937
VAP-Qu 0.05 ± 0.017 0.10 ± 0.013 0.09 ± 0.024 0.11 ± 0.017
VAP-M 0.12 ± 0.034 0. 12 ± 0.022 0.12 ± 0.020 0.10 ± 0.020
VAP-P 1.89 ± 0.300 1.94 ± 0.278 1.61 ± 0.248 2.14 ± 0.989
VAP-A 0.07 ± 0.028 0.31 ± 0.059 0.10 ± 0.022 0.31 ± 0.019
MLI 38 ± 3.4 141 ± 29.0 410 ± 59.0 320 ± 73.2
The cells were treated for 48 hours either with a VAP or with isolated MLI. The values were calculated as described under Material and Methods. 
The concentrations of mistletoe preparations are expressed as mg/ml; those of MLI as ng/ml.
BMC Complementary and Alternative Medicine 2007, 7:14 http://www.biomedcentral.com/1472-6882/7/14Werner, Hiscia AG, personal communication). All VAPs
had 20 mg of fermented extracts per ml and the lectin con-
tent was expressed relative to the extract weight, to allow
a better comparison with preparations standardized at
other concentrations. The mistletoe lectin concentration
was the highest in VAP-Qu with 53.5 ng/mg, approxi-
mately half this concentration in VAP-M and 40–50 times
lower in VAP-A and VAP-P (Table 3).
Effects of VAPs on bladder carcinoma cell growthFigure 2
Effects of VAPs on bladder carcinoma cell growth. J-82, T-24, TCC-SUP and UM-UC-3 bladder carcinoma cells were treated 
with different concentrations of VAP-Qu (❍), VAP-M (), VAP-P (Ќ) or VAP-A (), during 48 hours. Cell growth determina-
tion and data presentation as in legend to Fig. 1.
T-24J-82
TCC-SUP UM-UC-3
Table 2: Concentrations of various VAPs that are able to inhibit the growth of bladder carcinoma cells by 50 % (IC50 values).
T-24 TCC-SUP UM-UC-3 J-82
VAP-Qu 0.03 ± 0.003 0.08 ± 0.005 0.04 ± 0.003 0.17 ± 0.025
VAP-M 0.05 ± 0.005 0.10 ± 0.006 0.08 ± 0.003 0.60 ± 0.127
VAP-P 0.65 ± 0.047 0.86 ± 0.070 0.33 ± 0.039 2.95 ± 0.605
VAP-A 0.04 ± 0.002 0.05 ± 0.003 0.06 ± 0.006 0.49 ± 0.077
The cells were incubated in the presence of the corresponding mistletoe preparations for 48 hours and the values were calculated as described 
under Material and Methods. All concentrations are expressed as mg/ml.Page 5 of 7
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Our observations corroborate previous data showing that
VAPs were able to inhibit the in vitro growth of breast [9]
and bladder [11] carcinoma cells and that the extent of
this inhibitory effect varied with the mistletoe host tree
[10,17]. There are differences in the responsiveness of the
cell lines which were chosen to represent either breast or
bladder cancer. The four bladder carcinoma cell lines
turned out to be generally more sensitive to mistletoe
preparations than the four breast carcinoma cell lines.
These data strongly support clinical investigations on the
possible use of VAPs in the context of bladder cancer. It is
worth mentioning that the superficial forms of this malig-
nancy are good candidates for instillation (intravesical
therapy), which is likely to constitute an almost optimal
delivery system for VAPs at high local concentrations.
The IC50 values of VAP-Qu, VAP-M and VAP-A for the var-
ious breast and bladder carcinoma cell lines were lower
than those obtained with VAP-P, indicating that this latter
preparation has the weakest effect on viability/prolifera-
tion of carcinoma cells among the four VAPs tested. The
IC50 value of each preparation varied to some extent with
the cell line, which suggests that in the clinical context it
might be necessary to select the most effective preparation
to be used in each breast or bladder cancer patient. This
selection will probably be more complex than a mere
determination of the mistletoe lectin level of the various
extracts, because: a) the sensitivity profile towards isolated
MLI did not parallel that towards VAPs, and b) the mistle-
toe lectin content of the various extracts was not always
proportional to the corresponding cytotoxic effect.
The hypothesis that the mistletoe lectin content of a prep-
aration determines the magnitude of its inhibitory effect
on carcinoma cell growth seems to be confirmed by the
data obtained with VAP-P. This preparation, which had a
very low level of mistletoe lectin (1.3 ng/mg extract, Table
3), revealed the weakest cytotoxic effect. Strikingly, how-
ever, VAP-A had even slightly less mistletoe lectin than
VAP-P (1.0 ng/mg extract, Table 3), but the strongest or
second strongest cytotoxic effect of all four VAPs on MFM-
223, MCF-7, T-24, TCC-SUP, UM-UC-3 and J-82 carci-
noma cells. These results suggest that other components
might (also) play a role in the observed cytotoxic effect of
VAPs, and in particular of VAP-A. Viscotoxins, which are
usually present in the mistletoe preparations, are among
the possible candidates to have caused this additional
effect on cell growth [21,22]. This group of toxins includes
several isoforms whose levels vary among the VAPs, VAP-
P exhibiting the lowest levels of viscotoxins A1, A2 and A3
among the tested extracts [22]. Interestingly, VAP-A,
which revealed a strong cytotoxic effect on the various cell
lines, but whose mistletoe lectin content was very low
(approximately fifty times less than that of VAP-Qu, for
instance), is the preparation with the highest level of vis-
cotoxin A3 [22]. It is therefore conceivable that viscotoxin
A3 might play a major role in the cytotoxic effect of VAP-
A. Viscotoxin A3 is known to interact strongly with
biomembranes due to its pronounced hydrophobic char-
acter [21].
Should the effect of VAP-A be mainly mistletoe lectin-
independent and those of the other preparations mainly
mistletoe lectin-dependent, one would expect that VAP-A
would induce a different set of intracellular processes than
VAP-Qu or VAP-M. In line with these expectations, very
recent data on the gene expression profile in breast carci-
noma cells indicate that VAP-A induces molecular
changes on the cell-cell adhesion and cytoskeleton path-
ways, while VAP-Qu and VAP-M mainly affect the
immune defense and stress response genes [17].
Conclusion
Our work suggests that the differences among the various
VAPs might have been so far underestimated and that the
assumption that their cytotoxic effect relies exclusively on
the mistletoe lectin content is likely to be a simplification.
It is conceivable that VAP-A opens new possibilities to
explore the full potential of Viscum album in breast and in
bladder cancer therapy. To our knowledge, and in contrast
to the situation in breast cancer, the data concerning the
clinical use of mistletoe preparations on bladder cancer,
even though very promising, are scarce [23]. The potential
of mistletoe preparations in bladder cancer therefore
deserves clinical investigations.
Competing interests
Within the last five years AV, LR and APSW have received
occasional research funding from the pharmaceutical
Table 3: Mistletoe lectin concentration of the VAPs used in the experiments. 
Mistletoe preparation Lectin (ng/mg extract)
VAP-Qu 54± 1.45
VAP-A 1.0 ± 0.02
VAP-M 25 ± 0.03
VAP-P 1.3 ± 0.30
Data are shown as average ± S.D. of four measurements.Page 6 of 7
(page number not for citation purposes)
BMC Complementary and Alternative Medicine 2007, 7:14 http://www.biomedcentral.com/1472-6882/7/14Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
company Weleda AG, who produces VAP. MR has
received salaries from this company. The other authors
declare that they have no competing interests.
Authors' contributions
JE coordinated the practical part of the project and carried
out the experiments with the breast carcinoma cell lines,
LB performed the data analysis, BS and DP carried out the
cytotoxicity assays with the bladder carcinoma cell lines.
MR provided scientific support. KU isolated and purified
ML I. AV conceived the study and helped to draft the man-
uscript. APSW drafted and wrote the manuscript with LR.
All authors read and approved the final manuscript.
Acknowledgements
This study and the publication were financially supported by Weleda AG, 
4144 Arlesheim, Switzerland. Dr. M. Werner, from the Institute Hiscia 
Arlesheim, Switzerland, is gratefully acknowledged for the ELISA-based 
determinations of the mistletoe lectin content of the various VAPs. We 
would like to thank Nick Bell for his help in checking the English version.
References
1. Prosnitz RR Iglehart, J.D., Winer, E.P.: Breast Cancer.  In Clinical
oncology, a multidisciplinary approach for physicians and students Edited
by: Rubin P. New Youk ; 2001:267-299. 
2. Roach M, Small E, Reese DM, Carroll P: Urologic and male genital
cancers.  In Clinical oncology, a multidisciplinary approach for physicians
and students Edited by: Rubin P. New York ; 2001. 
3. Molassiotis A, Scott JA, Kearney N, Pud D, Magri M, Selvekerova S,
Bruyns I, Fernadez-Ortega P, Panteli V, Margulies A, Gudmundsdottir
G, Milovics L, Ozden G, Platin N, Patiraki E: Complementary and
alternative medicine use in breast cancer patients in Europe.
Support Care Cancer 2006, 14(3):260-267.
4. Schumacher K, Schneider B, Reich G, Stiefel T, Stoll G, Bock PR,
Hanisch J, Beuth J: Influence of postoperative complementary
treatment with lectin-standardized mistletoe extract on
breast cancer patients. A controlled epidemiological multi-
centric retrolective cohort study.  Anticancer Res 2003,
23(6D):5081-5087.
5. Semiglazov VF, Stepula VV, Dudov A, Schnitker J, Mengs U: Quality
of life is improved in breast cancer patients by Standardised
Mistletoe Extract PS76A2 during chemotherapy and follow-
up: a randomised, placebo-controlled, double-blind, multi-
centre clinical trial.  Anticancer Res 2006, 26(2B):1519-1529.
6. Kienle GS, Berrino F, Bussing A, Portalupi E, Rosenzweig S, Kiene H:
Mistletoe in cancer - a systematic review on controlled clini-
cal trials.  Eur J Med Res 2003, 8(3):109-119.
7. Kienle GS, Kiene H, Albonico HU: [Anthroposophic medicine:
health technology assessment report - short version.].  Forsch
Komplementarmed 2006, 13 Suppl 2:7-18.
8. Bantel H, Engels IH, Voelter W, Schulze-Osthoff K, Wesselborg S:
Mistletoe lectin activates caspase-8/FLICE independently of
death receptor signaling and enhances anticancer drug-
induced apoptosis.  Cancer Res 1999, 59(9):2083-2090.
9. Knopfl-Sidler F, Viviani A, Rist L, Hensel A: Human cancer cells
exhibit in vitro individual receptiveness towards different
mistletoe extracts.  Pharmazie 2005, 60(6):448-454.
10. Zuzak TJ, Rist L, Eggenschwiler J, Grotzer MA, Viviani A: Paediatric
medulloblastoma cells are susceptible to Viscum album
(mistletoe) preparations.  Anticancer Res 2006, 26:3485-3492.
11. Urech K, Buessing A, Thalmann G, Schaefermeyer H, Heusser P:
Antiproliferative effects of mistletoe (Viscum album L.)
extract in urinary bladder carcinoma cell lines.  Anticancer Res
2006, 26(4B):3049-3055.
12. Fischer S, Scheffler A, Kabelitz D: Stimulation of the specific
immune system by mistletoe extracts.  Anticancer Drugs 1997, 8
Suppl 1:S33-7.
13. Stein G, Henn W, von Laue H, Berg P: Modulation of the cellular
and humoral immune responses of tumor patients by mistle-
toe therapy.  Eur J Med Res 1998, 3(4):194-202.
14. Stein GM, Berg PA: Mistletoe extract-induced effects on immu-
nocompetent cells: in vitro studies.  Anticancer Drugs 1997, 8
Suppl 1:S39-42.
15. Heiny BM, Albrecht V, Beuth J: Correlation of immune cell activ-
ities and beta-endorphin release in breast carcinoma
patients treated with galactose-specific lectin standardized
mistletoe extract.  Anticancer Res 1998, 18(1B):583-586.
16. Pryme IF, Bardocz S, Pusztai A, Ewen SW: Suppression of growth
of tumour cell lines in vitro and tumours in vivo by mistletoe
lectins.  Histol Histopathol 2006, 21(3):285-299.
17. Eggenschwiler J, Patrignani A, Wagner U, Rehrauer H, Schlapbach R,
Rist L, Ramos MH, Viviani A: Gene expression profiles of differ-
ent breast cancer cells compared with their responsiveness
to fermented mistletoe (Viscum album L.) extracts Iscador
from oak (Quercus), pine (Pinus), white fir (Abies) and apple
tree (Malus) in vitro.  Arzneimittelforschung 2006, 56(6A):483-496.
18. Hostanska K, Vuong V, Rocha S, Soengas MS, Glanzmann C, Saller R,
Bodis S, Pruschy M: Recombinant mistletoe lectin induces p53-
independent apoptosis in tumour cells and cooperates with
ionising radiation.  Br J Cancer 2003, 88(11):1785-1792.
19. Schoffski P, Riggert S, Fumoleau P, Campone M, Bolte O, Marreaud S,
Lacombe D, Baron B, Herold M, Zwierzina H, Wilhelm-Ogunbiyi K,
Lentzen H, Twelves C: Phase I trial of intravenous aviscumine
(rViscumin) in patients with solid tumors: a study of the
European Organization for Research and Treatment of Can-
cer New Drug Development Group.  Ann Oncol 2004,
15(12):1816-1824.
20. Khwaja TA: Biopharmacological studies of different compo-
nents of Viscum album.  Anticancer Res 1990, 10:1374-1375.
21. Coulon A, Mosbah A, Lopez A, Sautereau AM, Schaller G, Urech K,
Rouge P, Darbon H: Comparative membrane interaction study
of viscotoxins A3, A2 and B from mistletoe (Viscum album)
and connections with their structures.  Biochem J 2003, 374(Pt
1):71-78.
22. Urech K, Schaller G, Jaggy C: Viscotoxins, mistletoe lectins and
their isoforms in mistletoe (Viscum album L.) extracts
Iscador.  Arzneimittelforschung 2006, 56(6A):428-434.
23. Elsässer-Beile U, Leiber C, Wetterauer U, Buhler P, Wolf P, Lucht M,
Mengs U: Adjuvant intravesical treatment with a standard-
ized mistletoe extract to prevent recurrence of superficial
urinary bladder cancer.  Anticancer Res 2005, 25:4733-4736.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6882/7/14/prepubPage 7 of 7
(page number not for citation purposes)
